PE20142445A1 - Compuestos de pirazol sustituidos como antagonistas de lpar - Google Patents

Compuestos de pirazol sustituidos como antagonistas de lpar

Info

Publication number
PE20142445A1
PE20142445A1 PE2014002212A PE2014002212A PE20142445A1 PE 20142445 A1 PE20142445 A1 PE 20142445A1 PE 2014002212 A PE2014002212 A PE 2014002212A PE 2014002212 A PE2014002212 A PE 2014002212A PE 20142445 A1 PE20142445 A1 PE 20142445A1
Authority
PE
Peru
Prior art keywords
compounds substituted
pirazole
lpar antagonists
lpar
antagonists
Prior art date
Application number
PE2014002212A
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142445(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20142445A1 publication Critical patent/PE20142445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referida a un compuesto derivado de pirazol de formula (I), donde X es oxigeno, nitrogeno o carbono; R1 es alquilo inferior; R2 es hidrogeno, halogeno, alcoxi, entre otros; R3 es ciclobutilo, oxetanilo, entre otros. Tambien esta referida a una composicion farmaceutica. Dichos compuestos tienen actividad antagonista del acido lisofosfatidico (LPA) y son utiles para el tratamiento de enfermedades y trastornos inflamatorios, tales como, por ejemplo, fibrosis pulmonar
PE2014002212A 2012-06-20 2013-06-17 Compuestos de pirazol sustituidos como antagonistas de lpar PE20142445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
PE20142445A1 true PE20142445A1 (es) 2015-01-28

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002212A PE20142445A1 (es) 2012-06-20 2013-06-17 Compuestos de pirazol sustituidos como antagonistas de lpar

Country Status (22)

Country Link
US (1) US20150259295A1 (es)
EP (1) EP2864294A1 (es)
JP (1) JP2015520201A (es)
KR (1) KR20150011003A (es)
CN (1) CN104411690A (es)
AU (1) AU2013279510A1 (es)
BR (1) BR112014031108A2 (es)
CA (1) CA2869602A1 (es)
CL (1) CL2014003242A1 (es)
CO (1) CO7160077A2 (es)
CR (1) CR20140516A (es)
EA (1) EA201492283A1 (es)
HK (1) HK1206341A1 (es)
IL (1) IL236091A0 (es)
IN (1) IN2014DN09347A (es)
MA (1) MA37765A1 (es)
MX (1) MX2014014105A (es)
PE (1) PE20142445A1 (es)
PH (1) PH12014502364A1 (es)
SG (1) SG11201407229UA (es)
UA (1) UA109867C2 (es)
WO (1) WO2013189862A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
CA2953472C (en) 2014-06-27 2022-08-02 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
BR112020011953A2 (pt) * 2017-12-19 2020-11-17 Bristol-Myers Squibb Company ácidos carbamoil ciclo-hexílicos n-ligados a pirazol como antagonistas de lpa
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4337641A1 (en) * 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AU2022405082A1 (en) 2021-12-08 2024-07-11 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US9272990B2 (en) * 2010-12-07 2016-03-01 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013025733A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
MA37765A1 (fr) 2017-04-28
BR112014031108A2 (pt) 2017-06-27
CN104411690A (zh) 2015-03-11
CL2014003242A1 (es) 2015-03-20
HK1206341A1 (en) 2016-01-08
AU2013279510A1 (en) 2014-10-16
CR20140516A (es) 2014-12-01
UA109867C2 (ru) 2015-10-12
KR20150011003A (ko) 2015-01-29
JP2015520201A (ja) 2015-07-16
MX2014014105A (es) 2015-03-05
US20150259295A1 (en) 2015-09-17
CO7160077A2 (es) 2015-01-15
EP2864294A1 (en) 2015-04-29
IN2014DN09347A (es) 2015-07-17
PH12014502364A1 (en) 2015-01-12
CA2869602A1 (en) 2013-12-27
EA201492283A1 (ru) 2015-04-30
IL236091A0 (en) 2015-02-01
SG11201407229UA (en) 2014-12-30
WO2013189862A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
PE20142445A1 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
PE20170206A1 (es) Inhibidores espirociclicos sustituidos de la autotaxina
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
IN2014MN01640A (es)
PE20141431A1 (es) USO DE COMPUESTOS TIPO ESTROBILURINA PARA COMBATIR HONGOS FITOPATOGENICOS RESISTENTES A INHIBIDORES DE Qo
CU20160180A7 (es) Compuestos de dihidroisoquinolinona sustituida
IN2014MN02459A (es)
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
MD20140124A2 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
IN2014CN04530A (es)
EA201390198A1 (ru) Гетероциклическое соединение
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
CO2018007663A2 (es) Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
CL2016000387A1 (es) Derivados de amida como antagonistas de ácido receptor lisofosfatidico
PE20141944A1 (es) N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina
MX2013008531A (es) Nuevos compuestos de benzodioxol-piperazina.

Legal Events

Date Code Title Description
FD Application declared void or lapsed